Recombinant Factor VIIa in a Case of Pontine Hemorrhage


Abstract

A 59-year-old lady presented with hypertensive hemorrhage involving the pons. Since she presented within 3 hours of onset of the stroke, recombinant factor VIIa was administered. From a state of altered sensorium there was a rapid recovery of consciousness followed by gradual improvement in limb weakness. Serial CT scans of the brain revealed no further expansion of the hematoma. The hematoma progressively resolved. Recombinant factor VIIa could be an attractive therapeutic option in treating hemorrhages at critical sites like brainstem where expansion of hematoma could be fatal.

CASE REPORT

A 59-year-old lady presented with vomiting followed by altered sensorium since 2 hours. She was a known hypertensive since 10 years and was on losartan (50 mg/d) and hydrochlorothiazide (12.5 mg/d). She was also a known diabetic since 15 years on regular therapy. Examination revealed: Pulse rate: 88/minute, regular; Respiratory rate: 16/minute; BP: 240/140 mm Hg; Temperature: 98.4 °F. Cardiorespiratory and per abdomen examinations were unremarkable. Neurologically she was in altered sensorium, was not arousable to loud call and could move left sided limbs minimally to deep pain. She had left gaze palsy. Pupils were 1.5 mm bilaterally. Hypotonia was noted over the right sided limbs that showed paucity of movements. Stretch reflexes were absent over the right side and brisk over the left side. Plantar response was extensor bilaterally.

Cranial, unenhanced CT scan revealed hyperdense lesion suggestive of hematoma (2.4 x 1.5 x 2.0 cm, approximate volume 3.6 cc, Fig. 1A) in the central pons, extending to the left side with mild effacement of prepontine cisterns. Coagulation profile was normal. Since she presented within 3 hours of onset of stroke, recombinant factor VIIa (2.4 mg intravenously over 5 minutes) was administered. Antihypertensive and antidiabetic drugs were continued. Her sensorium improved rapidly and she could obey commands by day 2. Cranial CT scan done on day 3 did not show any expansion of hematoma (Fig. 1B) and one done on day 7 (Fig. 1C) revealed reduced attenuation of the hyperdensity representing resolving hemorrhage. She could walk with support on day 22 and a repeat CT scan on day 25 (Fig. 1D) revealed total resolution of the hemorrhage.

DISCUSSION

Following ICH growth of hematoma is known to be an independent predictor of mortality and poor outcome. Causes of the expansion of the hematoma are: continued bleeding from the primary source and mechanical disruption of the surrounding vessels attributable to acute hypertension and a local coagulation defect. Hemostatic therapy offers the advantage of limiting the expansion of the growth, thus improving the outcome. This may be more relevant in the infratentorial compartment where the limitations of space may result in compression and mass effect over vital areas of the brain.

Recombinant human factor VII a (Novoseven) is a hemostatic agent used for treating hemophilia, congenital factor VII deficiency and Glanzman's thrombasthenia. Off-label use of the drug is now well known and it has been used in a variety of other conditions such as factor XI deficiency, Von Willebrand's disease, inherited disorders of
platelet functions like Bernard-Soullier syndrome, warfarin–associated hemorrhage and for reducing post operative blood loss. The drug has shown promise in the management of patients with primary ICH. In a multicenter phase 2 B trial involving 399 patients, treatment with recombinant factor VIIa was associated with reduced disability or death at 3 months compared to placebo. While use of this agent still remains investigational in ICH, a case may be made to consider its use in patients with hemorrhage in critical areas like brainstem. Our patient recovered rapidly clinically. Radiologically no further worsening of the hematoma size was noted that could have been spontaneous, attributable to BP control alone or to use of rFVIIa. The hemorrhage gradually reduced in size subsequently with further clinical improvement. Thus rFVIIa could be an attractive option in the management of brainstem hemorrhage.

REFERENCES